跳至主要内容
临床试验/NCT03826212
NCT03826212Unknown不适用

A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Soybean Germ Extract on Decrease of Body Fat

Chonbuk National University Hospital2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2019年6月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
80
试验地点
2
主要终点
Changes of body fat mass

研究概览

简要总结

This study was conducted to investigate the effects of daily supplementation of Soybean germ extract on decrease of body fat

详细描述

This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. 80 subjects were randomly divided into Soybean germ extract 1,600 mg or placebo group. The investigators measured Body Fat Mass, Percent Body Fat, Fat Free Mass, weight, and body mass index, etc.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
19 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age between 19 and 65 years
  • BMI 25~29.9 kg/m^2
  • After fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice

排除标准

  • Those who lost more than 10% of their weight within 3 months before the screening
  • Those who take a product(body fat improvement health functional foods, birth control pills, steroids, female hormone) that affects your weight within 4 weeks prior to the screening
  • Those with clinically significant severe cardiovascular, endocrine, immune, respiratory, liver, biliary, renal and urinary tract, neuropsychiatry, musculoskeletal, inflammatory and hematologic and gastrointestinal disorders
  • Diabetic patients taking oral hypoglycemic agents or insulin (based on screening subjects)
  • A person with a history of clinically significant hypersensitivity to soybeans
  • Those who have received antipsychotic medication within 2 months before screening
  • Anyone with substance abuse or suspicion
  • Those who participated in other clinical trials within 3 months before screening
  • Systolic Blood Pressure(SBP) 180 mmHg, Diastolic Blood Pressure(DBP) 110 mmHg or more
  • Menopausal woman
  • Laboratory test by show the following results
  • Aspartate Transaminase(AST), Alanine Transaminase(ALT) > Reference range 3 times upper limit
  • Serum Creatinine > 2.0 mg/dL
  • Pregnancy or breast feeding
  • Those who doesn't accept the implementation of appropriate contraception of a childbearing woman
  • Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.

研究组 & 干预措施

Soybean Germ Extract

Experimental

Soybean Germ Extract 1,600 mg/day for 12 weeks.

干预措施: Soybean Germ Extract (Dietary Supplement)

Placebo

Placebo Comparator

Placebo 1,600 mg/day for 12 weeks.

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Changes of body fat mass

时间窗: Baseline and 12 week

Body fat mass was measured in study baseline and 12 week

次要结局

  • Changes of Anthropometric indicate: body weight(Screening, baseline and 12 week)
  • Changes of energy expenditure Indicators: Uncoupling protein-1(UCP-1), Peroxisome proliferator-activated receptor gamma coactivator-1 α(PGC-1 α)(Baseline and 12 week)
  • Changes of Anthropometric indices: waist circumference, hip circumference(Screening, baseline and 12 week)
  • Changes of lipid metabolism indicators: Total cholesterol, Triglyceride, LDL-cholesterol, HDL-cholesterol(Baseline and 12 week)
  • Changes of percent body fat(Baseline and 12 week)
  • Changes of fat free mass(Baseline and 12 week)
  • Changes of Anthropometric indicate: body mass index(Screening, baseline and 12 week)
  • Changes of Anthropometric indicate: waist -hip circumference ratio(Screening, baseline and 12 week)
  • Changes of obesity-related hormones indicators: Adiponectin, Leptin(Baseline and 12 week)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Soo-Wan Chae

Principal Investigator, Clinical Trial Center for Functional Foods

Chonbuk National University Hospital

研究点 (2)

Loading locations...

相似试验